Affiliation:
1. Department of Laboratory Medicine Military Medical Center Sainte Anne Toulon France
2. Department of Blood Donation Screening French Military Blood Institute Clamart France
Abstract
AbstractBackground and ObjectivesScreening for red blood cell alloantibodies (RBC‐Ab) is a critical step in ensuring blood transfusion safety performed by blood donation screening laboratories. We aim to evaluate the prevalence of the RBC‐Ab among healthy blood donors.Materials and MethodsAntibody screening of serum of all voluntary blood donors was performed as a routine immune‐haematological procedure by a solid‐phase method on a fully automated immunohaematology analyser. Positive sera were further investigated to identify the specificity of RBC‐Ab by a commercially available red cell panel.ResultsBetween January 2012 and December 2021, a total of 212,218 donations were screened for the presence of RBC‐Ab, 74% from male donors (n = 157,898) and 26% from female donors (n = 54,320). Mean age at donation time was 32 ± 12 years. A total of 1007 donations were screened positive (0.47%), and 131 were confirmed positive for alloantibodies in their serum, yielding a prevalence of 0.06% (95% confidence interval: 0.05–0.07). Most frequent alloantibodies identified were of RH blood group system (64%), followed by anti‐MNS (19%), anti‐Kidd and Lewis (6% each) and anti‐KEL (4%). The results showed a statistically higher prevalence of alloantibodies in women than men. Our results showed a lower prevalence as compared to the available data, which might be related to our study population.ConclusionThe prevalence of positive antibody screening in healthy donors in this study was found to be 0.47%, while the prevalence of alloantibodies was 0.06%. The most common alloantibodies were anti‐RH1 (25%) and anti‐RH3 (24%).
Subject
Hematology,General Medicine
Reference13 articles.
1. Severe Hemolysis Due to a Donor Anti-D Antibody after Heart-Lung Transplantation: Association with Lung and Blood Chimerism
2. Code de la Santé Publique.Article D1221‐6 relatif aux analyses biologiques et tests de dépistage effectués à l'occasion de chaque don de sang ou de composant du sang destiné à la préparation de produits sanguins labiles à usage thérapeutique direct [Article D1221‐6 concerning biological analyses and screening tests performed during each blood donation or blood component intended for the preparation of labile blood products for direct therapeutic use].2018.
3. Journal Officiel de la République Française. Arrêté du 11 janvier 2022 modifiant l'arrêté du 17 décembre 2019 fixant les critères de sélection des donneurs de sang. [Order of January 11 2022 amending the Order of December 17 2019 establishing criteria for the selection of blood donors].2022.
4. Journal Officiel de la République Française. Arrêté du 15 mai 2018 fixant les conditions de réalisation des examens de biologie médicale d'immuno‐hématologie érythrocytaire [Order of May 15 2018 establishing performances of biological analysis of erythrocytic immuno‐hematology].2018.
5. Screening of blood donors for erythrocyte alloantibodies